Amneal to Virtually Participate at Upcoming Investor Conferences

November 12, 2021

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will virtually attend the following investor conferences:

Jefferies London Healthcare Conference
November 18, 2021
Investor Relations Hosted Meetings

Goldman Sachs Global Sustainability Forum
November 30, 2021
Investor Relations Hosted Meetings

Evercore ISI 4th Annual HEALTHCONx Virtual Conference
December 1, 2021
Management Hosted Meetings
Presentation – 8:25 a.m. Eastern Time

The presentation at the Evercore Conference will begin at 8:25 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at A replay of the webcast will be posted shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit

Tony DiMeo
Senior Director, Investor Relations

Source: Amneal Pharmaceuticals, Inc.